AETHLON MEDICAL INC
AEMDAethlon Medical Inc. (AEMD) is a biotechnology company focused on developing therapeutic and diagnostic technologies for infectious disease and cancer. The company is known for its Hemopurifier, a device designed to capture and remove viruses, tumor-derived antigens, and other pathogenic substances from the blood. Aethlon aims to address unmet medical needs through its innovative biofiltration and immunotherapy-based platforms.
Company News
Aethlon Medical announced that its independent Data Safety Monitoring Board (DSMB) has recommended advancing to the third and final cohort of its clinical trial for the Hemopurifier device. The DSMB found no safety concerns in the second cohort data, with no serious adverse events or dose-limiting toxicities reported. The final cohort will enroll...
Totaligent Inc. (OTC: TGNT) announced the execution of a binding Letter of Intent with GloMed Solutions, a Japanese medical aesthetics and biologics distributor generating ~$10M in annual revenue. The agreement establishes a joint venture integrating Totaligent's Aetherium Medical platform with GloMed's operations, while granting Totaligent a bin...
Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing the Hemopurifier device for cancer and infectious disease treatment, announced it will release fiscal Q3 2025 financial results on February 12, 2026, at 4:15 p.m. ET, followed by a management conference call at 4:30 p.m. ET. The Hemopurifier has received FDA Breakthrough Dev...
Aethlon Medical published preclinical study showing their Hemopurifier device can bind and remove extracellular vesicles from Long COVID patient samples, potentially decreasing inflammatory microRNAs and offering a novel therapeutic approach.
Aethlon Medical reported Q2 2025 financial results, highlighting clinical progress in oncology trials, ongoing Long COVID research, and significant cost reductions of 48% in operating expenses.
